Abstract Issue

Volume 13 Issue 6 (June) 2024

Original Articles

Assessing the Efficacy of Indacaterol/Mometasone versus Formoterol/Budesonide in Bronchial Asthma Patients
Dr. Zubair Ahmad Khan, Dr. Shoebul Haque, Dr. Farah Asif, Dr. Ajay Kumar Verma, Dr. Jyoti Bajpai, Dr. Rajendra Nath, Dr. Amod Kumar Sachan, Dr. Rakesh Kumar Dixit

Introduction: Asthma is a chronic inflammatory airway condition. It causes recurrent wheezing, coughing, breathlessness, and chest tightness. It significantly impacts global health. In India, it affects 17.23 million people (2.05% prevalence). Treatment focuses on inhaled corticosteroids and β2-agonists. Combination therapies are recommended for moderate to severe cases. Aims and Objectives: This study aims to evaluate and compare the effectiveness of Formoterol/Budesonide and Indacaterol/Mometasone as dry powder inhalers (DPI) in asthma patients, specifically in terms of Forced Expiratory Volume in one second (FEV1). Methods: Fifty-two patients with bronchial asthma were enrolled based on spirometry results and randomly assigned to two groups: Group A (24 patients) received a fixed-dose combination of Indacaterol (150 mcg) and Mometasone (160 mcg) once daily, while Group B (28 patients) received a fixed-dose combination of Formoterol (6 mcg) and budesonide (400 mcg) twice daily, both delivered as DPIs. Results: Initially, there was no significant difference in FEV1 between the groups at baseline. However, significant differences in post-observation mean FEV1 were observed between Group A and Group B at the 3-month (p = 0.001) and 6-month follow-ups (p = 0.045). Both groups showed a significant increase in FEV1 from pre- to post-observation at baseline, three months, and six months (p < 0.001 for both groups). Significant differences were also noted between the groups when comparing the mean change in FEV1 from pre- to post-bronchodilator (SABA) treatment at baseline (p = 0.001), 3-month (p < 0.001), and 6-month (p = 0.015) follow-ups. Conclusion: The Formoterol/Budesonide twice daily DPI combination proved to be more effective than the Indacaterol/Mometasone once daily DPI combination in improving lung function, as measured by FEV1.

 
Html View | Download PDF | Current Issue

Get In Touch

IJLBPR

322 Parlount Road Slough Berkshire SL3 8AX, UK

ijlbpr@gmail.com

Submit Article

© IJLBPR. All Rights Reserved.